Articles tagged "Co-stimulation"

2021 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
B. Oh¹, F. Messner², Y. Guo¹, G. Brandacher¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Visceral, Transplant and Thoracic Surgery, University of Innsbruck, Innsbruck, Austria
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
2021 American Transplant Congress
Belatacept Pharmacokinetics in Patients with and without Infection
A. Bickenbach¹, M. McGowan¹, B. Miyagawa², T. Mizuno², A. Shields³, A. Christianson¹, P. West-Thielke⁴, J. Leone⁵, E. Woodle¹, D. Kaufman⁶, A. Wiseman⁷, A. Vinks², R. Alloway¹
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's Med Center, Cincinnati, OH, ³Christ Hospital, Cincinnati, OH, ⁴UIC, Chicago, IL, ⁵Tampa Gen, Tampa, FL, ⁶U Wisconsin, Madison, WI, ⁷Centura Transplant, Denver, CO
*Purpose: Two belatacept(BELA) fixed mg/kg dosing regimens, less intense(LI) and more intense(MI) were compared. The LI regimen was approved due to the higher risk profile…
2020 American Transplant Congress
Belatacept Every Two Month Maintenance Dosing in Kidney Transplantation: A Randomized, Non-Inferiority Trial
I. R. Badell, R. Parsons, S. Mead, S. Thomas, G. Karadkhele, S. Pastan, C. Larsen
Emory University School of Medicine, Atlanta, GA
*Purpose: Maintenance immunosuppression with belatacept following kidney transplantation results in a reduced risk of patient death and graft loss as compared to calcineurin inhibitors. However,…
2020 American Transplant Congress
In Silico Deconvolution of Whole Blood RNA-Seq Data from Iscalimab Phase IIa Study in Renal Transplant Reveals Insights Into Mechanism of Action and Superiority of Iscalimab Compared to Tacrolimus
J. S. Rush
Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland
*Purpose: A recent Phase 2 clinical study indicated that iscalimab, a pathway blocking, non-depleting anti-CD40 antibody, showed non-inferiority on a composite clinical endpoint, and improved…
2020 American Transplant Congress
Belatacept in Kidney Transplant Recipients with Previous Non-Renal Solid Organ Transplants
O. Cristea, C. Larsen, I. Badell
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: Selective co-stimulatory blockade with belatacept has demonstrated long-term benefits in renal transplantation, with improved glomerular filtration rate and decreased risk of death and graft…
2020 American Transplant Congress
Dual and Opposite Costimulatory Targeting with a Novel Hybrid Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury in a Rat Bilateral Kidney Model
J. Guiteras¹, L. De Ramon¹, E. Crespo¹, N. Bolaños¹, P. Fontova¹, M. Jarque¹, A. Torija¹, O. Bestard², J. Grinyó², J. Torras²
¹Experimental Nephrology, IDIBELL, Hospitalet de Llobregat, Spain, ²Bellvitge University Hospital, Hospitalet de Llobregat, Spain
*Purpose: Many studies showed the CTLA4 effectiveness in the inhibition of CD28-CD80/86 costimulatory pathway in transplant and autoimmune diseases. Furthermore, the PD1-PDL1/2 interaction has been…
2020 American Transplant Congress
Is it Time for Immune Screening for Belatacept-Treated Stable Kidney Transplant Patients for Adjust the Immunosuppression?
M. C. Rial¹, F. Caro², N. Ambrosi², D. Guerrieri², A. Calleri¹, E. Chuluyan¹, D. Casadei¹
¹ITAC, Buenos Aires, Argentina, ²CEFYBO, UBA, Buenos Aires, Argentina
*Purpose: Belatacept is a co-stimulation blocker for primary maintenance immunosuppression in kidney transplant recipients. The goal of this work was to study the immunological status…
2020 American Transplant Congress
A Novel Injectable Hydrogel-Based Approach to Localize and Tune the Actuation of Enhanced Costimulation Blockade to the Strength of Transplant Rejection
A. Komin¹, C. Liang², P. Majumder², X. Calderon-Colon³, O. Tiburzi³, M. Iglesias Lozano¹, Y. Zhang¹, G. Brandacher¹, J. Patrone³, J. Schneider², G. Raimondi¹
¹Johns Hopkins School of Medicine, Baltimore, MD, ²NIH National Cancer Institute, Frederick, MD, ³JHU Applied Physics Laboratory, Laurel, MD
*Purpose: Complications from long-term use of calcineurin inhibitors remain a major issue for transplant patients and alternative therapies are needed. The clinical efficacy of CTLA4-Ig…
2020 American Transplant Congress
Analysis of Rejection, Rejection Therapy and Renal Function in the BEST Trial
H. Kuzaro¹, A. R. Shields², A. Wiseman³, S. Tremblay¹, A. Christianson¹, D. Kaufman⁴, J. Leone⁵, A. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH, ³U Colorado, Denver, CO, ⁴U Wisconsin, Madison, WI, ⁵Tampa General, Tampa, FL, ⁶U Minnesota, Minneapolis, MN, ⁷UIC, Chicago, IL
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal) compared two belatacept (BELA)-based early corticosteroid withdrawal (ESW) regimens and alemtuzumab (ALEM) or rabbit antithymocyte globulin (rATG)…
2020 American Transplant Congress
Effector Differentiation of Endogenous Antigen-Specific CD8⁺ T Cells is Selectively Limited by CTLA-4 Ig
S. M. Krummey, K. P. Tong, M. L. Ford
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: Costimulation blockade with belatacept (CTLA-4 Ig) offers improved renal function and reduced toxicity following transplantation compared to calcineurin inhibitors. Nonetheless, episodes of acute T…

« Previous Page
1
…
4
5
6
7
8
…
30
Next Page »